ExPLoRNA Therapeutics, a Warsaw, Poland-based biotech company, raised $813.578 from Bill & Melinda Gates Foundation.
Led by CEO Jacek Jemielity, ExPLoRNA Therapeutics specializes in novel cap analogs, the starting part of mRNA that is crucial for enabling production of the encoded protein. The technology increases protein production beyond scale observable so far with other standard cap analogs.
The company intends to use the funds for a 14-month project that aims to better understand the benefits of its cap analogs, especially in terms of reducing the mRNA dose needed for therapeutic effects in the settings of vaccination and monoclonal antibody production. The planned experiments include the use of clinically validated lipid nanoparticle (LNP) formulations from Acuitas Therapeutics. Acuitas is known for its role in providing the LNP technology for one of the only two regulatory-approved mRNA-based COVID-19 vaccines.
FinSMEs
09/12/2022